Crinetics Pharmaceuticals stock gains 2.80% amid ENDO2026 presentations, Crinetics updates

Traders Union
All News
Companies
Crinetics Pharmaceuticals up 2.80% today

Highlights

CRNX faces persistent downward pressure, trading below key moving averages across short, medium, and long timeframes.
Technical signals are predominantly bearish, with momentum indicators supporting the likelihood of further declines rather than sustained gains.
CRNX is expected to remain range-bound between $33.00 and $36.00; a drop below $33.00 signals heightened downside risk.

Technical pressure persists as price holds below key moving averages

CRNX ($34.47) trades below the SMA-20 ($35.01), SMA-50 ($37.46), and SMA-200 ($41.65), signaling persistent downward pressure in the short, medium, and long term. The Ichimoku Kijun at $37.96 stands above the current price, acting as immediate resistance. Near-term support is identified at the SMA-20 ($35.01), while key support lies at the SMA-50 ($37.46). Immediate resistance is the Ichimoku Kijun at $37.96, with the SMA-100 ($40.00) serving as key resistance.

Mixed momentum signals as consolidation follows recent rebound

Momentum signals on D1 are mixed—MACD shows strong bearish momentum, while ADX remains neutral, suggesting no clear trend dominance. RSI is in neutral territory but tilts bearish, and Stoch RSI signals overbought conditions, indicating potential for a short-term pullback. CCI is neutral, while BBP shows a slight oversold reading, favoring sellers intraday. The Awesome Oscillator is neutral and does not strongly support the current trend. CRNX is trading at $34.47, up from last week's close of $32.92, marking a weekly gain of 4.71%. The price is in the middle of the weekly range, with weekly volatility standing at 9.72%. The stock shows consolidation after a rebound from the weekly low.

Range-bound bias as bearish signals outweigh upside potential

Looking ahead, the expected range for the coming week is $33.00 to $36.00, staying well within the ±20% band around the current price and in line with recent volatility. The probability of further price increase is very low (less than 20%), as W1 indicators—RSI, ADX, MACD, and MA-50—all point to a bearish bias, making a decline more likely. Baseline scenario: CRNX remains range-bound between $33.00 and $36.00 as sellers cap advances. Bullish scenario: a close above immediate resistance ($37.96) could trigger a move toward higher resistance, though current signals make this unlikely. Bearish scenario: a drop below $33.00 opens the path to further weakness, with increased risk if weekly support fails. This outlook situates CRNX closer to its 52-week low ($25.83) than its high ($57.99), reinforcing a cautious near-term stance.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Earlier, analysts noted that Crinetics Pharmaceuticals was experiencing continued bearish momentum, with technical indicators pointing to persistent downside risk. In the current environment, traders should monitor for sustained shifts in volume or sentiment, as a move above key resistance could signal a meaningful change in trend.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.